Back to results

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. (SafrTravlT1D)

Primary Purpose

Diabetes Mellitus, Type 1

Status

Completed

Phase

Phase 4

Locations

United States

Study Type

Interventional

Intervention

Insulin Degludec

Insulin Glargine

TRESIBA® FLEXTOUCH®

LANTUS® SOLOSTAR® INSULIN PEN

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 1 focused on measuring Insulin Degludec, Insulin Glargine, Air Travel, Continuous Glucose Monitor

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Males or females ≥18 and ≤65 years of age.
Type 1 diabetes mellitus (diagnosed clinically and treated with multiple daily injections of insulin) for ≥12 months.
HbA1c <10% within 30 days of being enrolled in the study
Current treatment with any basal insulin analogue as the once daily basal insulin given in the evening (22) and no fewer than three injections with rapid acting bolus insulin (e.g. insulin aspart, insulin lispro, or insulin glulisine) as mealtime bolus insulin therapy.
No contraindication to long-haul travel.
No recurrent severe hypoglycemia (more than 1 severe hypoglycemic event requiring hospitalization during the last 12 months), or hypoglycemia unawareness as judged by a score of >4 on the Gold score (23), or hospitalization for diabetic ketoacidosis during the previous 6 months.
Willing and able to use a continuous glucose monitoring device (e.g. Dexcom G4).
Ability to self-manage insulin therapy (verbal confirmation at screening visit) of a changed bolus insulin dose the preceding 2 months prior to screening.
Ability and willingness to adhere to the protocol, including performance of self-monitored blood glucose (SMBG) readings and self-adjustment of insulin doses according to protocol.
-

Exclusion Criteria:

Current use of an insulin pump.
Use within the last 3 months prior to enrollment visit 1 of any glucose-lowering drug other than insulin.
Initiation or significant change of any systemic treatment which, in the investigator's opinion, could interfere with glucose metabolism, such as systemic corticosteroids, beta-blockers or monoamine oxidase inhibitors (inhaled corticosteroids allowed).
Proliferative retinopathy or maculopathy requiring treatment, according to the investigator.
Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures.
Any clinically significant disease or disorder, which in the investigator's opinion could interfere with the results of the trial.
Mental incapacity, psychiatric disorder, unwillingness or language barriers precluding adequate understanding or cooperation, including subjects not able to read or write, and known or suspected abuse of alcohol, narcotics, or illicit drugs.
Known or suspected allergy to any of the trial products or related products.
Receipt of any investigational drug or participation in other trials within 1 month prior to Visit 1.
-

Sites / Locations

Sansum Diabetes Research Institute
inControl Diabetes Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Insulin Degludec

Insulin Glargine U100

Arm Description

Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Degludec and the TRESIBA® FLEXTOUCH® pens during a long-haul flight and randomized to this arm first or second.

Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Glargine U100 and the LANTUS® SOLOSTAR® INSULIN PEN during a long-haul flight and randomized to this arm first or second.

Outcomes

Primary Outcome Measures

Continuous Glucose Monitoring - Time in Range (70-140 mg/dl)

Time in range (70-140 mg/dl) [percentage of glucose readings or hours per day] by continuous glucose monitoring (CGM) during the initial 24 hours local time (starting within 2 hours after arriving) in Newark, NJ after flying 9-10 hours West to East (from Honolulu, HI) and after the return journey from Newark to Honolulu (flying East to West).

Secondary Outcome Measures

Continuous Glucose Monitoring - Time in Range (70-180 mg/dl)

Time in range (70-180 mg/dl) [percentage of glucose readings or hours per day] by continuous glucose monitoring (CGM) during the first 24 hours after arriving in HNL and EWR (starting within 2 hours after arrival).

Mean ± SD CGM Glucose (mg/dl)

Mean ± standard deviation of CGM glucose (mg/dl) by CGM during the flight and during the 72 hours at the destination

CGM % Time <70 mg/dl

% time <70 mg/dl by CGM

CGM % Time 70-180 mg/dl

% time 70-180 mg/dl by CGM

CGM % Time >180 mg/dl

% time >180 mg/dl by CGM

CGM - Coefficient of Variation (CV)

Coefficient of variation of CGM values - glycemic variability (CV, %)

CGM Fasting Blood Glucose (FBG)

Fasting Blood Glucose (FBG) was determined using CGM at each destination on the morning after arrival.

Liverpool Jet-Lag Questionnaire

This is a Questionnaire about jet-lag and fatigue administered at the destinations after arrival. Jet Lag is rated on a 0-10 scale (0 - insignificant jet lag to 10 - very bad jet lag). Fatigue is rated on a scale of -5 to +5 (more fatigue to less fatigue).

Sleep Quantity Measured by ActiGraph

Measurement of sleep duration (TST - Total sleep time in minutes)

Sleep Efficiency Measured by ActiGraph

Measurement of sleep efficiency (SE% - total sleep time in minutes divided by time in bed in minutes)

Full Information

NCT ID

NCT03668808

First Posted

September 11, 2018

Last Updated

October 6, 2022

Sponsor

Sansum Diabetes Research Institute

Collaborators

Novo Nordisk A/S

1. Study Identification

Unique Protocol Identification Number

NCT03668808

Brief Title

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.

Acronym

SafrTravlT1D

Official Title

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Travelling Across Multiple Time Zones. A Pilot Study.

Study Type

Interventional

2. Study Status

Record Verification Date

October 2022

Overall Recruitment Status

Completed

Study Start Date

November 16, 2018 (Actual)

Primary Completion Date

September 19, 2020 (Actual)

Study Completion Date

September 19, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Sansum Diabetes Research Institute

Collaborators

Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Yes

Product Manufactured in and Exported from the U.S.

Yes

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of the proposed study is to compare insulin Degludec [TRESIBA® (insulin degludec injection)] with insulin Glargine U100 [Lantus® (insulin glargine injection)] to determine the basal insulin of choice for adults with type 1 diabetes (T1D) who fly non-stop across multiple time zones. With the introduction of Degludec as basal insulin for T1D and the opportunity to vary time of injection between 8 and 40 hours, the use of Degludec as a basal insulin may make it easier for both people living with T1D and diabetologists to plan long-haul travel compared to the use of existing basal insulins when crossing multiple time zones.The study hypothesis is that once daily Degludec as the basal insulin will provide better glycemic control for people with type 1 diabetes on multiple daily injections who are traveling non-stop across multiple time zones than once daily Glargine U100.

Detailed Description

This study will be an open-label, single center, pilot study. Participants will be randomized to either Glargine U100 or Degludec as the basal insulin, then a 2 week break, and followed by a cross-over to the other insulin. Each study period will begin in Honolulu, Hawaii (HI) (airport code HNL) with a non-stop flight to Newark, New Jersey (NJ) (EWR) lasting approximately 10 hours with a 6 hour time difference between destinations. After up to 72 hours in EWR, participants will return to Honolulu and spend up to 72 hours at that destination. Investigators plan to recruit 25 adults with established T1D currently being treated with multiple daily injections of insulin (MDI).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Diabetes Mellitus, Type 1

Keywords

Insulin Degludec, Insulin Glargine, Air Travel, Continuous Glucose Monitor

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 4

Interventional Study Model

Crossover Assignment

Model Description

Subjects will begin in Honolulu, HI (HNL), fly to Newark (EWR) where they will stay for up to 72 hours followed by a return long-haul flight back to Honolulu with up to 72 hours at this destination. This journey will be repeated after a 2 week period when subjects return to their original insulin treatment regimen and then switch to the alternative basal insulin.

Masking

None (Open Label)

Allocation

Randomized

Enrollment

25 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Insulin Degludec

Arm Type

Experimental

Arm Description

Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Degludec and the TRESIBA® FLEXTOUCH® pens during a long-haul flight and randomized to this arm first or second.

Arm Title

Insulin Glargine U100

Arm Type

Active Comparator

Arm Description

Intervention Type

Drug

Intervention Name(s)

Insulin Degludec

Other Intervention Name(s)

Tresiba

Intervention Description

Subjects will use Insulin Degludec (Tresiba) with TRESIBA® FLEXTOUCH® pens as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

Intervention Type

Drug

Intervention Name(s)

Insulin Glargine

Other Intervention Name(s)

Lantus

Intervention Description

Subjects will use Insulin Glargine (Lantus) with LANTUS® SOLOSTAR® INSULIN PEN as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

Intervention Type

Device

Intervention Name(s)

TRESIBA® FLEXTOUCH®

Other Intervention Name(s)

Insulin Degludec

Intervention Description

Subjects will use Tresiba FlexTouch pens when using Tresiba as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

Intervention Type

Device

Intervention Name(s)

LANTUS® SOLOSTAR® INSULIN PEN

Other Intervention Name(s)

Insulin Glargine

Intervention Description

Subjects will use Lantus SoloStar insulin pens when using Lantus as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

Primary Outcome Measure Information:

Title

Continuous Glucose Monitoring - Time in Range (70-140 mg/dl)

Description

Time Frame

During the initial 24 hours local time and starting within 2 hours after arrival

Secondary Outcome Measure Information:

Title

Continuous Glucose Monitoring - Time in Range (70-180 mg/dl)

Description

Time Frame

During the initial 24 hours local time and starting within 2 hours after arrival

Title

Mean ± SD CGM Glucose (mg/dl)

Description

Mean ± standard deviation of CGM glucose (mg/dl) by CGM during the flight and during the 72 hours at the destination

Time Frame